Abstract
A substantial pharmacologic advantage might be gained by delivering chemotherapy directly into the peritoneum or pleura for tumors confined to these serous cavities. Peak drug levels in ascites after intraperitoneal administration range from 30 to W times that achieved in plasma after intravenous (IV) dosage. (Table 1) If a drug has a high level of hepatic extraction, the plasma concentration after intracavitary (IC) administration of a given dose may be substantially lower than that after IV administration.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE: Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res (42): 4265–4269, 1982.
Ozols RF, Willson JKV, Grotzinger KR, Young RC: Cloning of human ovarian cancer cells in soft agar from malignant effusions and peritoneal washings. Cancer Res (HO): 2743–2747, 1980.
Ozols RF, Willson JKV, Weltz MD, Grotzinger KR, Myers CE, Young RC: Inhibition of human ovarian cancer colony formation by Adriamycin and its major metabolites. Cancer Res (40): 4109–4112, 1980.
Speyer JL, Collins JM, Dedric RL, Brennan MF, Londer H, DeVita VT, Myers CE: Phase I and pharmacological studies of 5–Fluorouracil administered intraperitoneally. Cancer Res (40): 567–572, 1980.
Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT: High-volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother Pharmacol (1): 1161–1166, 1978.
Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Ballow JW, Brennan MF, Dedrick RJ, DeVita VT: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res (41): 55–59, 1981.
Howell SB, Pfeifle CE, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M: c. Ann Intern Med (97): 845–851, 1982.
Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr: Pharmacokinetic study of intraperitoneal (IP) Cisplatin (CP) in patients with malignant ascites. Proc ASCO (1): 22 (C–87), 1982.
Paladine WP, Cunningham TJ, Sponzo R. Donovan M, Olson K, Horton J: Intracavitary bleomycin in the management of malignant effusions. Cancer (38): 1903–1908, 1976.
Dedrick RL, Myers CL, Bungay PM, DeVita VT Jr: Pharmokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (62): 1–11, 1978.
Ozols RF, Looker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC: Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (39): 3209–3214, 1979.
Roboz J, Chahinian AP, Tosk J, Holland JF: Transport of doxorubicin from peritoneal fluid to plasma in malignant mesothelioma. Proc AACR (22): 229 (#906), 1981.
Kefford Rf, Woods RL, Fox RM, Tattersall MHN: Intracavitary Adriamycin, nitrogen mustard and tetracycline in the control of malignant effusions. Med J Australia (2): 447–448, 1980.
Tattersall MHN, Fox RM, Newlands ES, Woods RL: Intracavitary doxorubicin in malignant effusions. Lancet (i): 390, 1979.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Antman, K., Osteen, R., Montella, D. (1984). A Phase I Trial of Intracavitary Doxorubicin (Adriamycin) Alternating with Cisplatin. In: Howell, S.B. (eds) Intra-Arterial and Intracavitary Cancer Chemotherapy. Developments in Oncology, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3843-7_15
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3843-7_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3845-1
Online ISBN: 978-1-4613-3843-7
eBook Packages: Springer Book Archive